Investors purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading hours on Wednesday after an insider sold shares in the company. $142.68 million flowed into the stock on the tick-up and $86.52 million flowed out of the stock on the tick-down, for a money net flow of $56.16 million into the stock. Of all equities tracked, Gilead Sciences had the 15th highest net in-flow for the day. Gilead Sciences traded down ($0.25) for the day and closed at $80.69Specifically, insider John C. Martin sold 50,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares in the company, valued at $224,302,912.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 14,435 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.54, for a total value of $1,177,029.90. The disclosure for this sale can be found here. Insiders sold 432,768 shares of company stock valued at $33,919,138 over the last 90 days. 1.30% of the stock is currently owned by corporate insiders.
GILD has been the subject of several recent analyst reports. BMO Capital Markets dropped their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, October 27th. Mizuho set a $77.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Sunday, October 29th. Argus lowered Gilead Sciences from a “buy” rating to a “hold” rating and increased their price objective for the stock from $73.25 to $73.77 in a research note on Monday, November 13th. Finally, Credit Suisse Group reiterated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday, December 7th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $86.92.
The stock has a market cap of $103,690.00, a price-to-earnings ratio of 10.34, a PEG ratio of -1.85 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same quarter last year, the business earned $2.70 earnings per share. equities analysts expect that Gilead Sciences, Inc. will post 6.24 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 annualized dividend and a yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is currently 27.08%.
A number of institutional investors have recently bought and sold shares of GILD. Keel Point LLC lifted its stake in Gilead Sciences by 0.4% in the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 12 shares during the period. Paradigm Financial Advisors LLC lifted its stake in Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 26 shares during the period. Princeton Portfolio Strategies Group LLC lifted its stake in Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after buying an additional 41 shares during the period. Auxier Asset Management lifted its stake in Gilead Sciences by 1.4% in the second quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock valued at $479,000 after buying an additional 96 shares during the period. Finally, Edmonds Duncan Registered Investment Advisors LLC lifted its stake in Gilead Sciences by 1.6% in the second quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company’s stock valued at $452,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 75.71% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/23/traders-buy-shares-of-gilead-sciences-gild-on-weakness-following-insider-selling.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.